You are here

Xtandi

Is This Pfizer's Next Mega-Blockbuster Cancer Drug?

Motley Fool

Tue, 09/27/16 - 10:51 am

Pfizer: Hospira Is Future; Xtandi Is Today's Meal

Yahoo/GuruFocus

Mon, 09/19/16 - 06:04 pm

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St

Wed, 09/14/16 - 11:53 pm

clinical trials

Array Biopharma

Mast Therapeutics

Threshold Pharmaceuticals

Cerulean Pharma

Vertex Pharmaceuticals

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St

Thu, 09/8/16 - 09:50 am

clinical trials

Celldex Therapeutics

Cerulean Pharma

Anthera Pharmaceuticals

Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021

Market Realist

Mon, 08/29/16 - 04:16 pm

prostate cancer

How Mylan And Pfizer Could Cause A Major Biotech Backlash

Forbes

Thu, 08/25/16 - 09:47 am

What Pfizer Gets in Its $14 Billion Medivation Deal

Motley Fool

Tue, 08/23/16 - 10:02 am

prostate cancer

Pfizer spent $14 billion on a company with just one approved drug — here's why that's a game changer

Yahoo/Business Insider

Mon, 08/22/16 - 11:45 am

prostate cancer

Pfizer agrees to buy cancer behemoth Medivation for $14 billion

Marketwatch

Mon, 08/22/16 - 10:00 am

Xtandi's blockbuster Q2 growth shows why Big Pharma wants a Medivation deal

Fierce Pharma

Thu, 08/11/16 - 11:38 pm

Medivation: Xtandi Global Sales Rose 53% in 1Q16

Yahoo/Market Realist

Tue, 05/17/16 - 05:30 pm

Analyzing Medivation’s Growth Opportunity with Xtandi

Yahoo/Market Realist

Thu, 05/12/16 - 04:42 pm

metastatic castration-resistant prostate cancer

prostate cancer

Here's What Medivation Said In Its Rejection Letter To Sanofi

Yahoo/Benzinga

Sat, 04/30/16 - 10:47 am

Shifting prostate landscape underpins Sanofi’s Medivation offer

EP Vantage

Fri, 04/29/16 - 09:15 am

prostate cancer

A frustrated Sanofi makes $9.3 billion bid for Medivation and its cancer drug

Stat

Thu, 04/28/16 - 09:39 am

Report: AstraZeneca considering bid for cancer biotech Medivation

BioPharma Dive

Mon, 04/18/16 - 09:44 am

Patent Palooza: One Patent Battle in Hep C, And Another Patent Brawl Brewing On Capitol Hill

Motley Fool

Mon, 04/4/16 - 07:59 am

Ionis Pharmaceuticals

Gilead Sciences

Congress just fired a shot against its next drug-pricing target, and its shares took a hit

Yahoo/Business Insider

Mon, 03/28/16 - 09:10 pm

Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat

Fierce Pharma Marketing

Wed, 11/11/15 - 09:10 pm

4 Blockbuster Drugs Whose Sales Could Easily Double

Motley Fool

Mon, 10/26/15 - 08:46 am

Bristol-Myers Squibb

Pages